Modification of D-Galactosamine-Induced Liver Injury in the Rat by Spironolactone

Mihas, A. A.; Foster, Meta; Barnes, Susan; Mihas, T. A.; Hirschowitz, B I; Spenney, Jerry G.

doi:10.1159/000137258

Cited by 1 publication

(1 citation statement)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rat models, spironolactone decreased ALT and liver toxicity induced by dimethyl mercury 36 or D-galactosamine. 37 In this study, HOMA-IR was significantly decreased within group 2, whereas QUICKI showed a trend towards increase (meaning IR improvement) in the same group without reaching the level of statistical significance. This is not unexpected, since it has been previously reported that both HOMA and QUICKI reflect insulin action expressed by clamps, 16,17 but they do not offer the same information about IR, thereby expressing different aspects of insulin action.…”

Section: Discussioncontrasting

confidence: 46%

Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease

Polyzos

Zafeiriadou

Patsiaoura

et al. 2011

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Aim:The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of insulin resistance and nonalcoholic fatty liver disease (NAFLD). The beneficial effect of spironolactone in a mouse model with diabetes and NAFLD has recently been reported. The main aim was assessment of the effect of spironolactone on serum metabolic parameters and insulin resistance in patients with NAFLD. Methods: This study includes preliminary results of a single-centre randomised controlled trial of treatment with vitamin E (group 1, 10 patients) versus spironolactone plus vitamin E (group 2, 10 patients) in biopsy-proven NAFLD. Serum transaminases, lipids, potassium, sodium, glucose and insulin were measured, and homeostatic model assessment-insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated before and 8 weeks after baseline assessment. Results: Insulin was decreased within group 2 (15.3 ± 2.7 at baseline vs. 10.3 ± 5.0 at week 8, p = 0.013). Although no difference in glucose was observed, HOMA-IR significantly decreased (4.4 ± 0.9 vs. 2.8 ± 0.5, respectively, p = 0.047). QUICKI was increased, but not statistically significantly. Conclusions: Spironolactone and vitamin E combined therapy seems to exhibit a favourable effect on serum insulin and HOMA-IR in patients with NAFLD. If validated in a large-scale clinical trial, it may prove an inexpensive therapeutic approach for the management of NAFLD patients.

show abstract

Section: Discussioncontrasting

confidence: 46%